News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Atox Bio Granted Orphan Drug Designation for AB103 for the Treatment of Necrotizing Soft Tissue Infections (NSTI)



10/25/2011 10:03:36 AM

NESS ZIONA, Israel--(BUSINESS WIRE)--Atox Bio today announced that the FDA Office of Orphan Products Development has granted orphan drug designation for AB103 for the treatment of necrotizing soft tissue infections.

Necrotizing soft tissue infections (NSTI) includes several distinctive clinical diagnoses that share clinical features representing the most severe types of infections involving the skin, skin structures and soft tissue and having a high mortality rate. Currently, there are no approved treatments for NSTI. The current principles of management include early diagnosis with prompt and repeated surgical debridement, aggressive resuscitation and physiologic support, in addition to antimicrobial drugs.

Read at BioSpace.com


comments powered by Disqus
Atox Bio
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES